SCHEMBL26241675

SCHEMBL26241675

CCC(=O)Oc1cccc2ccc(/C=C/c3ccccc3Cl)nc12

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KMT2A Q03164 18/20 0.58
▸ MEN1 O00255 17/20 0.58
▸ NPC1 O15118 14/20 0.58
▸ AGTR1 P30556 4/20 0.58
▸ HSP90AA1 P07900 1/20 0.58
▸ FNTA P49354 1/20 0.52
▸ FNTB P49356 1/20 0.52
▸ RAB9A P51151 12/20 0.50
▸ MAPT P10636 9/20 0.50
▸ NPSR1 Q6W5P4 4/20 0.50
▸ TDP1 Q9NUW8 3/20 0.50
▸ HTT P42858 2/20 0.50
▸ CYP1A2 P05177 1/20 0.50
▸ CYP3A4 P08684 1/20 0.50
▸ CYP2D6 P10635 1/20 0.50
▸ CYP2C19 P33261 1/20 0.50
▸ RECQL P46063 1/20 0.50
▸ CASP3 P42574 1/20 0.48
▸ SENP7 Q9BQF6 1/20 0.48
▸ SENP6 Q9GZR1 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12282407 0.77 AGTR1 (0.60) KMT2AMEN1NPC1AGTR1RAB9A
SCHEMBL16971024 0.74 KMT2A (1.00) KMT2AMEN1NPC1AGTR1HSP90AA1
SCHEMBL16971022 0.74 KMT2A (1.00) KMT2AMEN1NPC1AGTR1HSP90AA1
SCHEMBL10767985 0.73 MEN1 (0.54) KMT2AMEN1NPC1RAB9AMAPT
SCHEMBL27952547 0.70 KMT2A (0.58) KMT2AMEN1NPC1AGTR1RAB9A
SCHEMBL12281112 0.70 KMT2A (0.60) KMT2AMEN1NPC1AGTR1RAB9A
SCHEMBL9799609 0.70 ELANE (0.46) KMT2AMEN1MAPTNPSR1HTT
SCHEMBL578720 0.70 ELANE (0.46) KMT2AMEN1MAPTNPSR1HTT
SCHEMBL15547750 0.69 KMT2A (0.43) KMT2AMEN1CYP1A2CYP3A4CYP2D6
SCHEMBL10769266 0.69 MEN1 (0.47) KMT2AMEN1NPC1AGTR1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11701374-B1 8-hydroxy quinoline derivatives for enhancing telomerase reverse transcriptase (TERT) expression SIERRA SCIENCES, INC. (US) 2023-07-18 — — US disclosed
US-11701374-B1 8-hydroxy quinoline derivatives for enhancing telomerase reverse transcriptase (TERT) expression SIERRA SCIENCES, INC. (US) 2023-07-18 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11701374-B1 8-hydroxy quinoline derivatives for enhancing telomerase reverse transcriptase (TERT) expression TERT, TERF2, RNGTT KMT2A 280/4885MEN1 3550/4885NPC1 3227/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback